These innovative agents represent a significant advancement in the treatment of type 2 diabetes. Retatrutide, a triple GLP-1 and GIP receptor agonist, demonstrates exceptional efficacy in reducing blood glucose levels. https://tessrixl070857.loginblogin.com/47129933/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide